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Association between Antipsychotics-Induced Restless Legs 
Syndrome and Tyrosine Hydroxylase Gene Polymorphism 
 
 
 
ObjectiveaaRestless legs syndrome (RLS) has been reported to be more prevalent in schizo-
phrenic patients who take antipsychotics. The cause of RLS is unknown but associated with 
dopaminergic deficiency. Tyrosine hydroxylase (TH) is the enzyme responsible for catalyzing 
the conversion of L-tyrosine to DOPA. The purpose of this study is to determine whether 
the TH gene Val81Met polymorphism is associated with antipsychotic-induced RLS. 
Methodsaa One hundred ninety Korean schizophrenic patients were evaluated by the di-
agnostic criteria of the International RLS Study Group (IRLSSG). The genotyping was per-
formed by PCR-based methods. 
ResultsaaOf the one hundred ninety schizophrenic patients, 44 (23.2%) were found to 
have RLS. Although there were no significant associations between TH genotypes or allele 
frequencies and RLS, when separate analyses were performed by sex (male or female), we 
detected significant differences in the frequencies of the genotype (χ
2=6.15, p=0.046) and 
allele (χ2=4.67, p=0.031) of the TH gene Val81Met polymorphism between those with and 
without RLS in the female patients. 
ConclusionaaThese findings suggest that the TH gene Val81Met SNP might be associated 
with antipsychotic-induced RLS in female schizophrenic patients. 
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Introduction 
 
Restless legs syndrome (RLS) is characterized by an unpleasant sensation in, and the 
urge to move the legs.
1 RLS is a common disease, but is often underdiagnosed, undiag-
nosed or misdiagnosed as other psychiatric, neurologic or musculoskeletal systemic
disease.
2,3 The estimated prevalence of RLS depends on ethnic samples or the design 
of studies, and varies widely from 1% to 15%.
4,5 According to recent epidemiologic 
studies in Korea, the prevalence of RLS is 12.1% in Korean adults aged 40-69 years.
6
Other epidemiological studies in Korea have shown that the prevalence of RLS is ap-
proximately 7.5%, and among those only 24.3% receive treatment.
7  
The cause of RLS is not yet clear, but a leading pathophysiologic theory involves
dopaminergic deficiency.
8 The fact that RLS patients show RLS symptom relief after 
taking levodopa
9 or dopamine agonists
8,10,11 is evidence for the theory that dopaminergic 
deficiency causes RLS. In addition, RLS symptoms are relieved quickly and nearly
completely with low-dose medication, which indicates an improvement of symptoms 
due to activation of the dopamine system itself rather than from other secondary changes 
associated with activation of the dopamine system.
12 Patients who take antipsychotics 
show RLS more frequently, supporting the RLS dopaminergic abnormality theory. 
Antipsychotic-induced RLS is known to be caused by blocking dopamine receptors.
13
Tyrosine hydroxylase (TH) is the enzyme responsible for catalyzing the conversion 
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of the amino acid L-tyrosine to dihydroxyphenylalanine 
(DOPA), and is a rate-limiting enzyme.
14 TH is found in 
the cytoplasm of noradrenergic and dopaminergic neuronal 
cells in the locus coeruleus, ventral tegmental area, sub-
stantia nigra, adrenal medulla, and sympathetic ganglia.
15 
The TH gene is located in 11p15.5.
15,16 Activation of TH 
reflects the increase of dopamine production. The most 
common mutation of TH is Val81Met polymorphism in 
exon 2, but it is not yet clear how Val81Met polymor0-
phism changes TH activity.
17,18 The difference of function-
al activity in TH caused by the Val81Met polymorphism 
is not known till today.
19  
Desautels et al.
20 analyzed the Val81Met polymorphism 
using a sample of 92 patients with RLS and 182 con-
trols. No significant difference was found. As TH plays a 
very important role in generating dopamine, many studies 
suggest the association of the Val81Met polymorphism 
and movement disorders, such as Parkinson’s disease (PD) 
and RLS.
18,21 The purpose of the present study was to 
determine whether Val81Met polymorphism is associat-
ed with antipsychotic-induced RLS. 
 
Methods 
 
Subjects 
One hundred ninety unrelated Korean schizophrenia 
patients were enrolled at Korea University Hospital and 
collaborating hospitals. They were aged between 22 and 
66 years (mean±SD: 39.6±9.2 years). All of the subjects 
were diagnosed with schizophrenia by experienced psy-
chiatrists according to the Korean version of the Struc-
tured Clinical Interview for Diagnostic and Statistical 
Manual of Mental Disorders fourth edition, and had been 
treated with antipsychotics. All of the participants pro-
vided written informed consent to participate, and the 
study protocol was approved by the Ethics Committee 
of Korea University Hospital. Some findings from these 
subjects have been reported previously.
22,23 Exclusion 
criteria were as followings: 1) the patients were too psy-
chotic, agitated or mutistic to be inteviewed, 2) patients 
presented with other Axis I diagnoses, mental retardation, 
neurological disorder, head injury, history of alcohol or 
other substance abuse, and 3) patients had serious medi-
cal diseases or other conditions that could induce second-
ary RLS, such as severe anemia, renal failure, radiculo-
pathy and peripheral neuropathy. 
 
Assessment of symptoms 
We gathered data on each patient’s sociodemographics, 
duration of illness, prescribed antipsychotics and chlorpro-
mazine equivalent dosage. Every assessment was per-
formed during the daytime (between 09:00 and 17:00 h). 
RLS was assessed using the International Restless Legs 
Syndrome Study Group (IRLSSG) diagnostic criteria and 
a paradigm of questions used in epidemiologic studies of 
RLS. All subjects were asked about the four essential 
diagnostic criteria of RLS; i) the urge to move the legs, ii) 
unpleasant sensations in the legs, iii) symptoms worsen-
ing during rest and relief by movement, and iv) symptoms 
worsening in the evening or at night. If the unpleasant 
sensations were caused by arthritis, neuropathy, sports in-
juries, vascular problems, positional discomfort, sleep 
starts, simple cramping, and psychotic agitation or tactile 
hallucinations, we did not consider them as symptoms of 
RLS. All four essential diagnostic criteria of RLS were re-
quired for patients who were diagnosed with RLS, and 
those that did not meet all four criteria were included in 
the non-RLS group. The severity of RLS symptoms was 
assessed using the IRLSSG rating scale (IRLS) for RLS.
24  
The evaluation of the degree of psychiatric symptoms 
was done using the Brief Psychiatric Rating Scale (BP-
RS),
25 which is an 18-item observer scale designed to as-
sess patients with major psychiatric disorders. 
 
Genotyping 
Venous blood was drawn from each individual, and ge-
nomic DNA was isolated using Accuprep Genomic DNA 
Extraction Kit (Bioneer, Korea) according to standard pro-
cedures. Analysis was done using Polymerase Chain Reac-
tion (PCR) and PCR-based Restriction fragment length 
polymorphism (PCR-RFLP). PCR amplification was per-
formed with the forward primer 5’-ATC CCC TGC CTC 
TGT GTG CCA T-3’ and the reverse primer 5’-TCA GGA 
ACT CAG CCC ACA CAG C-3’, giving a 404 base pair 
(bp) product. The PCR product was digested by the re-
striction enzyme NIaIII for approximately 3 hours at 37℃, 
then the reaction mixture was analyzed by 2% agarose 
gel electrophoresis to ensure correct amplification of the 
DNA fragment. NIaIII cleaves the Met81 allele into three 
fragments of 173, 140, 91bp, and the Val81 allele into two 
fragments of 313 and 91bp.
26 
 
Statistical analyses 
We performed the Hardy-Weinberg equilibrium test 
to assess the goodness of fit of the data. We analyzed the 
categorical data using the chi-square test, and evaluated 
the differences between continuous variables to establish 
whether there was an association between RLS and geno-
types by using Student’s t-test or one-way analysis of 
variance. Statistical analyses were carried out using Sta-
tistical Package for Social Sciences (SPSS) for Windows 
(SPSS Inc., Chicago, IL). All statistical analyses were 
two-tailed, and the level of statistical significance was set 
at p<0.05.  
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Results 
 
Among the 190 schizophrenia patients of our sample, 
44 (23.2%) patients were diagnosed as having RLS, and 
146 (76.8%) were included in the non-RLS group based 
on the IRLSSG diagnostic criteria. The sex, age, height, 
weight, duration of illness, duration of medication, treat-
ment, chlorpromazine equivalents, proportion of typical 
(or atypical) antipsychotics did not differ significantly 
between the RLS and the non-RLS (Table 1). However, 
IRLS score and BPRS score were subsequently signifi-
cantly higher in the RLS than in the non-RLS (t=9.746, 
p<0.001; t=2.266, p=0.025) (Table 1).  
The genotype frequencies did not deviate from Hardy-
Weinberg equilibrium. There were no significant differ-
ences in the genotype, allele and allele carrier frequencies 
among the RLS and the non-RLS groups. However, when-
separate analyses were performed by sex (male or female), 
we detected significant differences in the frequencies of 
the genotype (χ2=6.15, p=0.046) and allele (χ2=4.67, p= 
0.031) of TH gene Val81Met polymorphism between RLS 
and nonRLS only in the female subjects. There were no 
significant differences in the genotype, allele, and Met al-
lele carrier frequencies between RLS and non-RLS in 
male subjects (Table 2). 
Discussion 
 
In this study, we investigated the association between 
antipsychotic-induced RLS and the TH gene Val81Met 
polymorphism, among schizophrenia patients who took 
antipsychotics. There were no significant differences in 
the genotype, allele and Met allele carrier frequencies bet-
ween RLS and non-RLS groups. However, when separate 
analyses were performed by sex (male or female), there 
were significant differences in gene variants between 
RLS and non-RLS only in female subjects. 
Epidemiological studies of RLS have previously report-
ed higher prevalence in women than men. Berger et al.
27 
reported the overall prevalence of RLS was 10.6%, and 
women were twice as likely than men to be affected in the 
German population. Hogl et al.
28 conducted a community-
based study of prevalence of RLS, and the prevalence of 
RLS was 10.6% and higher in women (14.2% in women, 
6.6% in men) in the Austrian population as well.   
Kritzer et al.
29 suggested estrogen and progesterone ap-
pear to be potent regulators of the catecholamine innerva-
tion of the primate prefrontal cortex. Such regulation is 
anticipated in the sex difference observed in prefronto-
cortical development and function. McDermott et al.
30 di-
rectly compared striatal dopamine metabolism in gonadec-
TABLE 2. Genotypes, allele, and allele carrier frequencies of Val81Met polymorphism of the tyrosine hydroxylase gene among schizophrenic 
patients with and without RLS 
Genotypes Allele  Allele  carrier   
  
Met/Met Met/Val  Val/Val   
 
Met Val   
 
Met+ Met-   
Total RLS  (N=44) 29  (65.9%) 12  (27.3%) 3  (6.8%)  χ2=2.030    0.78 0.22  χ2=0.51   0.93  0.07  χ2=0.110 
 Non  RLS  (N=146) 81  (55.5%) 57  (39.0%) 8  (5.5%) p=0.363    0.75 0.25  p=0.474    0.95  0.05  p=0.739 
Female RLS  (N=23) 17  (73.9%)  04 (17.4%) 2  (8.7%)  χ2=6.150    0.83 0.17  χ2=4.670   0.91  0.09  χ2=1.080 
 Non  RLS  (N=61) 31  (50.8%) 28  (45.9%) 2  (3.3%) p=0.046    0.65 0.35  p=0.031    0.97  0.03  p=0.299 
Male RLS  (N=21) 12  (57.1%)  08 (38.1%) 1  (4.8%)  χ2=0.220    0.76 0.24  χ2=0.002   0.95  0.05  χ2=0.140 
 Non  RLS  (N=85) 50  (58.8%) 29  (34.1%) 6  (7.1%) p=0.896    0.76 0.24  p=0.967    0.93  0.07  p=0.704 
RLS: restless legs syndrome, N: number of subjects 
 
TABLE 1. Differences in the demographics and clinical characteristics between RLS group and non-RLS group in schizophrenia
 RLS  (N=44) Non-RLS  (N=146) t-test  or χ2-test 
Age  039.1±10.2 40.0±9.0 t=-0.61  p=0.544 
Sex (M/F) 21/23  85/61  χ2=1.51 p=0.219 
Height (cm) 163.0±8.70 165.2±7.60 t=-1.64  p=0.103 
Weight (kg)  065.9±10.9  064.9±11.0 t=0.52  p=0.604 
Duration of illness (years) 14.7±7.3 15.8±7.5 t=-0.82  p=0.416 
Cumulative exposure to neuroleptics (years) 13.3±6.5 13.1±6.9 t=0.14  p=0.887 
Chlorpromazine equivalent  501.3±387.4  0531.2±469.5 t=-0.38  p=0.702 
Type of antipsychotics (typical/atypical) 6/38  26/120  χ2=0.44 p=0.506 
Education (years) 11.2±3.3 11.5±3.0 t=-0.70  p=0.484 
RLS score  19.0±5.6  05.7±8.5 t=9.75  p<0.001 
BPRS score  18.3±7.2 15.6±6.8 t=2.27  p=0.025 
The values are mean±standard deviation (SD). RLS: restless legs syndrome, BPRS: brief psychiatric rating scale 
  
 
 
 
 
Antipsychotics-Induced RLS and TH Gene 
214 Psychiatry Invest 2009;6:211-215 
tomized male and female CD-1 mice treated with estro-
gen or oil vehicle. Estrogen-treated female mice showed 
increased dopamine release compared to oil-treated fe-
males. Estrogen did not affect striatal dopamine concen-
tration or release in males. These results suggest that un-
der conditions of equal hormonal status, striatal dopamine 
turnover and concentrations are differentially affected by 
sex. The results also suggest that estrogen can exert sub-
stantial effects on striatal dopamine metabolism by acting 
specifically in females to increase neuronal dopamine syn-
thesis and release.   
Some researches reported that antiestrogens (AEs) and 
estradiol (E) change dopamine turnover rates.
31 In addi-
tion, Desautels et al.
32 suggested that the high activity al-
lele of the monoamine oxidase-A (MAO-A) gene may be 
involved in modifying the severity of RLS manifesta-
tions in females. 
TH plays an important role in the synthesis of dopa-
mine. Furthermore, in the previous study, subchronic anti-
psychotic medication reduced TH immunostaining in the 
striatum and caused shrinkage of dopaminergic cell bodies 
in substantia nigra.
33 Lerner et al.
34 reported changes of 
TH Vmax (maximal transport capacity) after chronic halo-
peridol administration and suggested that TH protein ex-
pression is elevated by long-term haloperidol treatment. 
Therefore, we hypothesized TH to be associated with 
antipsychotic-induced RLS in schizophrenia patients.   
Because the symptoms of RLS are similar to those of 
akathisia, the differentiation is important. Although RLS 
and akathisia can overlap in some patients,
22 we tried our 
best to differentiate between them based on the facts that 
symptoms of akathisia include the inner feeling of rest-
lessness, it is not restricted to the legs, and is a daytime 
phenomenon.  
This study has several limitations. First, we did not 
check serum iron levels. Because iron is the main cofactor 
of TH's catalysis,
14 it is possible that our results reflect 
differential levels of serum iron. Second, our subjects were 
taking a various antipsychotics which have different mech-
anisms of action. However, chlorpromazine equivalents, 
and a proportion of typical (or atypical) antipsychotics 
did not differ significantly among the RLS and the non-
RLS groups. Therefore, taking a broad spectrum of anti-
psychotics should not affect significantly the results. Third, 
we cannot exclude presence of population stratification 
bias. However, we do not think that stratification bias 
should be considered seriously in our sample because the 
Korean population is characterized by a genetic homoge-
neity.
35 Fourth, the relatively small sample size limits the 
generalization of our findings. Because our sample size 
is relatively small, our data cannot exclude the possibility 
that TH Val81Met polymorphism has an influence on sus-
ceptibility to antipsychotic-induced RLS.   
Taken these limitations together, further investigations 
involving additional genes and markers and larger sam-
ples are warranted to fully understand the genetic patho-
physiology of RLS. 
 
Acknowledgments 
This study was supported by the Research Fund of the Environmental 
Health Center Project (2007), Ministry of the Environment, Republic of 
Korea. 
 
REFERENCES 
1. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Mont-
plaisi J, et al. Restless legs syndrome: diagnostic criteria, special consi-
derations, and epidemiology. A report from the restless legs syndrome 
diagnosis and epidemiology workshop at the National Institutes of 
Health. Sleep Med 2003;4:101-119. 
2. Sachdev P, Longragan C. The present status of akathisia. J Nerv Ment 
Dis 1991;179:381-391. 
3. Dressler D, Thompson PD, Gledhill RF, Marsden CD. The syndrome 
of painful legs and moving toes. Mov Disord 1994;9:13-21. 
4. Bjorvatn B, Leissner L, Ulfberg J, Gyring J, Karlsborg M, Regeur L, 
et al. Prevalence, severity and risk factors of restless legs syndrome in 
the general adult population in two Scandinavian countries. Sleep Med 
2005;6:307-312. 
5. Garcia-Borreguero D, Egatz R, Winkelmann J, Berger K. Epidemio-
logy of restless legs syndrome: the current status. Sleep Med Rev 
2006;10:153-167. 
6. Kim J, Choi C, Shin K, Yi H, Park M, Cho N, et al. Prevalence of 
restless legs syndrome and associated factors in the Korean adult 
population: the Korean Health and Genome Study. Psychiatry Clin 
Neurosci 2005;59:350-353. 
7. Korean Sleep Society. Epidemiology of restless legs syndrome. Rest-
less Legs Syndrome (RLS) Media Conference 2006. 
8. Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH. An up-
date on the dopaminergic treatment of restless legs syndrome and pe-
riodic limb movement disorder. Sleep 2004;27:560-583. 
9. Kaplan PW, Allen RP, Buchholz DW, Walters JK. A double-blind, 
placebo-controlled study of the treatment of periodic limb movements 
in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993;16: 
717-723. 
10. Silber MH, Ehrenberg BL, Allen RP, Buchfuhrer MJ, Earley CJ, 
Hening WA, et al. An algorithm for the management of restless legs 
syndrome. Mayo Clin Proc 2004;79:916-922. 
11. Thorpy MJ. New paradigms in the treatment of restless legs syndrome. 
Neurology 2005;64(12 supple 3):S28-S33. 
12. Chang Ho Yun MD. Pathophysiology of the Restless Legs Syndrome: 
dopamine and Iron. J Kor Sleep Soc 2006;3:22-28. 
13. Kryger MH, Roth T, Dement WC. Principles and Practice of sleep 
medicine, 5th ed, Philadelphia: Elsevier Saunders; 2005. 
14. Kaushik P, Gorin F, Vali S. Dynamics of tyrosine hydroxylase mediat-
ed regulation of dopamine synthesis. J Comput Neurosci 2007;22: 
147-160. 
15. O’Malley KL, Anhalt MJ, Martin BM, Kelsoe JR, Winfield SL, Ginns 
EI. Isolation and characterization of the human tyrosine hydroxylase 
gene: identification of 5’ alternative splice sites responsible for mul-
tiple mRNAs. Biochemistry 1987;26:6910-6914. 
16. Chitbangonsyn SW, Mahboubi P, Walker D, Rana BK, Diggle KL, 
Timberlake DS, et al. Physical mapping of autonomic/sympathetic 
candidate genetic loci for hypertension in the human genome: a soma-
tic cell radiation hybrid library approach. J Hum Hypertens 2003;17: 
319-324.  
 
 
 
 
CH Cho et al. 
www.psychiatryinvestigation.org 215 
17. Lüdecke B, Bartholomé K. Frequent sequence variant in the human 
tyrosine hydroxylase gene. Hum Genet 1995;95:716. 
18. Benmoyal-Segal L, Soreq H. Gene-environment interactions in spora-
dic Parkinson’s disease. J Neurochem 2006;97:1740-1755. 
19. Ishiguro H, Arinami T, Saito T, Akazawa S, Enomoto M, Mitushio H, 
et al. Systematic search for variations in the tyrosine hydroxylase gene 
and their associations with schizophrenia, affective disorders, and al-
coholism. Am J Med Genet 1998;81:388-396. 
20. Desautels A, Turecki G, Montplaisir J, Ftouhi-Paquin N, Michaud M, 
Chouinard VA, et al. Dopaminergic neurotransmission and restless legs 
syndrome: a genetic association analysis. Neurology 2001;57:1304-
1306. 
21. Kunugi H, Kawada Y, Hattori M, Ueki A, Otsuka M, Nanko S. As-
sociation study of structural mutations of the tyrosine hydroxylase 
gene with schizophrenia and Parkinson’s disease. Am J Med Genet 
1998;81:131-133. 
22. Kang SG, Lee HJ, Jung SW, Cho SN, Han C, Kim YK, et al. Charac-
teristics and clinical correlates of restless legs syndrome in schizophre-
nia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1078-1083. 
23. Kang SG, Lee HJ, Choi JE, Park YM, Park JH, Han C, et al. Asso-
ciation study between antipsychotics-induced restless legs syndrome 
and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes 
in schizophrenia. Neuropsychobiology 2008;57:49-54. 
24. Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. 
Validation of the International Restless Legs Syndrome Study Group 
rating scale for restless legs syndrome. Sleep Med 2003;4:121-132. 
25. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol 
Rep 1962;10:799-812. 
26. Lee HJ, Kang SG, Choi JE, Park YM, Lim SW, Rhee MK, et al. No 
Evidence for Association between Tyrosine Hydroxylase Gene Val81-
Met Polymorphism and Susceptibility to Tardive Dyskinesia in Schi-
zophrenia. Psychiatry Invest 2009;6:108-111. 
27. Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and 
the risk of restless legs syndrome in the general population. Arch 
Intern Med 2004;164:196-202. 
28. Hogl B, Kiechl S, Willeit J, Saletu M, Frauscher B, Seppi K, et al. 
Restless legs syndrome: a community-based study of prevalence, se-
verity, and risk factors. Neurology 2005;64:1920-1924. 
29. Kritzer MF, Kohama SG. Ovarian hormones influence the morphol-
ogy, distribution, and density of tyrosine hydroxylase immunoreactive 
axons in the dorsolateral prefrontal cortex of adult rhesus monkeys. J 
Comp Neurol 1998;395:1-17. 
30. McDermott JL, Liu B, Dluzen DE. Sex differences and effects of 
estrogen on dopamine and DOPAC release from the striatum of male 
and female CD-1 mice. Exp Neurol 1994;125:306-311. 
31. Toney TW, Katzenellenbogen BS. Antiestrogen action in the medial 
basal hypothalamus and pituitary of immature female rats: insights 
concerning relationships among estrogen, dopamine, and prolactin. 
Endocrinology 1986;119:2661-2669. 
32. Desautels A, Turecki G, Montplaisir J, Brisebois K, Sequeira A, Adam 
B, et al. Evidence for a genetic association between monoamine oxi-
dase A and restless legs syndrome. Neurology 2002;59:215-219. 
33. Marchese G, Casu MA, Bartholini F, Ruiu S, Saba P, Gessa GL, et al. 
Sub-chronic treatment with classical but not atypical antipsychotics 
produces morphological changes in rat nigro-striatal dopaminergic 
neurons directly related to “early onset” vacuous chewing. Eur J Neu-
rosci 2002;15:1187-1196. 
34. Lerner P, Nosé P, Gordon EK, Lovenberg W. Haloperidol: effect of 
long-term treatment on rat striatal dopamine synthesis and turnover. 
Science 1977;197:181-183. 
35. Han GR, Lee YW, Lee HL, Kim SM, Ku TW, Kang IH, et al. A 
Korean population study of the nine STR loci FGA, VWA, D3S1358, 
D18S51, D21S11, D8S1179, D7S820, D13S317 and D5S818. Int J 
Legal Med 2000;114:41-44.
 